Exelixis | EXEL - 销售和管理费用



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.89B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


销售和管理费用 更改 日
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bayer EUR 3.96B 267M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Cytokinetics USD 104.4M 499K 2026-06
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Genmab DKK 205M 39M 2026-06
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Pfizer USD 3.41B 496M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sanofi EUR 2.49B 252M 2026-03
Takeda JPY 286.51B 5.48B 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Xencor USD 77.54M 4.59M 2026-06